Skip to main content

Advertisement

Fig. 1 | BMC Gastroenterology

Fig. 1

From: Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial

Fig. 1

Fasting and postprandial FGF19 serum concentrations measured by quantitative sandwich enzyme-linked immunosorbent assay (ELISA). Comparison of FGF19 values between healthy controls (N = 16), overweight (N = 14) and obese (N = 12) patients with non-alcoholic fatty liver disease (NAFLD) at baseline (0 h), 2, 4 and 6 h after the oral fat tolerance test (OFTT). Significant difference between basal (0 h) FGF19 concentrations in controls and obese NAFLD patients [controls 178.5 (101.0–257.0) vs. obese 116.0 (51.0–134.3) pg/ml, medians (IQRs), p = < 0.05, Mann-Whitney-U-test). At 2 h, lower FGF19 values in overweight NAFLD patients in comparison to controls [overweight 163.0 (78.5–168.3) vs. controls 244.5 (161.5–377.5) pg/ml, medians (IQRs), p = 0.004, Mann-Whitney-U-test), * outlier

Back to article page